View More Recent Stories

May 7, 2025 10:19AM Stifel Reiterates Buy Rating on Apogee Therapeutics Inc (APGE)
Mar 10, 2025 02:16PM TD Cowen Reiterates Buy Rating on Apogee Therapeutics Inc (APGE)
Mar 3, 2025 11:15AM Apogee Therapeutics Inc (APGE) PT Raised to $86 at Jefferies
Mar 3, 2025 06:20AM Apogee Therapeutics (APGE) Announces Positive Interim Phase 1 Results from the APG990 Healthy Volunteer Trial
Dec 12, 2024 06:20AM Guggenheim Reiterates Buy Rating on Apogee Therapeutics Inc (APGE)
Nov 27, 2024 06:07AM Apogee Therapeutics Inc (APGE) PT Raised to $110 at Guggenheim, Best Idea reiterated
Nov 12, 2024 01:43PM Stifel Reiterates Buy Rating on Apogee Therapeutics Inc (APGE)
Oct 24, 2024 08:02AM Apogee Therapeutics (APGE) Announces Results Up to 9 Months from Phase 1 Trial of APG777
Sep 30, 2024 06:11AM Guggenheim Reiterates Buy Rating on Apogee Therapeutics Inc (APGE)
Sep 30, 2024 05:44AM BTIG Reiterates Buy Rating on Apogee Therapeutics Inc (APGE)
Sep 9, 2024 07:01AM Apogee Therapeutics (APGE) Appoints Jeff S. Hartness as CCO
Aug 20, 2024 06:06AM BTIG Reiterates Buy Rating on Apogee Therapeutics Inc (APGE)
Aug 19, 2024 07:02AM Apogee Therapeutics (APGE) Announces First Participants Dosed in Phase 1 Clinical Trial of APG990
Aug 12, 2024 06:31AM Apogee Therapeutics (APGE) Reports Q2, Provides Pipeline Update
Jul 18, 2024 08:06AM NewAmsterdam Pharma (NAMS) Announces Appointments of Mark C. McKenna and Wouter Joustra to its Board of Directors
View More Recent Stories